Related Blog Posts from the Wikinvest Wire

Abbott Laboratories (ABT) recently announced that the company has launched ACCELERATOR a3600 – its next-generation track system to increase efficiency in laboratories. A laboratory automation track system, ACCELERATOR a3600 enables processing for up to 3,600 samples per hour along with handling multiple tube sizes and types simultaneously. Moreover, this system automates routine, manual tasks which in turn [...]

AbbVie (ABBV) recently confirmed its sales figures for 2012 and provided guidance for 2013 as an independent company. AbbVie came into existence earlier this year following its separation from Abbott Laboratories (ABT). AbbVie said that excluding the negative impact of currency fluctuation (3%), pharmaceutical segment revenues grew more than 8% in the fourth quarter of 2012 [...]

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories (ABT), and...

Abbott Laboratories: A company I loved  At the beginning of this year, Abbott Laboratories (ABT) completed the spin-off of its branded pharmaceutical business. This business is now a separate publicly traded company, calling itself AbbVie Inc. (ABBV). I have long been a fan of Abbott Laboratories as a diversified health care company with operations in medical devices, diagnostics, branded pharmaceuticals and nutrition among other businesses. It's been in business since 1888 and it's been...

I have been a shareholder of Abbott Laboratories for several years. I liked the fact that the company was constantly undervalued, and also managed to offer a very attractive yield plus an above average dividend growth. My last addition to my position occurred in the final weeks of 2012. In my last analysis of the stock, I was bullish on its business going forward. On January 1, 2013, Abbott Laboratories split into two companies, one which retained its name Abbott Laboratories...

Abbott Laboratories (ABT) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into a phase III study, ABSORB III, in the US. The randomized, controlled study will enroll 2,250 patients and will compare Absorb BVS’s performance to the company's Xience drug eluting stents. We note that Absorb is available in Europe and some [...]

Shares of Abbott Laboratories (NYSE: ABT) surged as much as 3% on Thursday after the company announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received U.S. Food and Drug... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. This dividend champion has boosted distributions for 40 years in a row. The company’s last dividend increase was in February 2012 when the Board of Directors approved a 6.30% increase to 51 cents/share. The company’s peer group includes Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY) and Merck (MRK). Over the past decade this dividend growth stock has...

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is planning to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair...

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. This dividend champion has boosted distributions for 40 years in a row. The company’s last dividend increase was in February 2012 when the Board of Directors approved a 6.30% increase to 51 cents/share. The company’s peer group includes Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY) and Merck (MRK). Over the past decade this dividend growth stock has delivered...

Abbott Laboratories (ABT) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). TransVax, a vaccine in-licensed by Astellas from Vical Inc. (VICL), is being developed for the prevention of cytomegalovirus (CMV) reactivation in transplant patients. Under the collaboration, patients will be monitored for CMV [...]

The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney, and Abbott Laboratories, La Monica does not own positions in any individual stocks. When your stock is trading at just 4 times earnings estimates for the next year, you'd think that [...]

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is planning to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair...

Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories’ (ABT) anti-inflammatory drug Humira. The data was presented at the European League Against Rheumatism (EULAR) annual European congress of rheumatology. The randomized, investigator-blinded multinational [...]

St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each [...]

Healthcare products maker Abbott Laboratories (ABT: News ) on Wednesday reported a 44 percent surge in profit for the first quarter, helped by higher sales of its drugs and nutritional products. Both revenues and ongoing earnings per share topped analysts' expectations. Buoyed by the results, Abbott raised its earnings outlook [...]

In a previous article, I discussed how dividend investors should analyze the earnings of each company they own in detail, in order to obtain an understanding behind the real valuation behind the business. I discussed how AT&T (T) and Coca-Cola (KO) appeared cheaper than usual. Today, I will discuss another example of a situation, where I had to dig deeper, before obtaining the full picture behind Abbott Lab’s valuation. I have been a shareholder of Abbott Labs (ABT) for many years. Just...

In a previous article, I discussed how dividend investors should analyze the earnings of each company they own in detail, in order to obtain an understanding behind the real valuation behind the business. I discussed how AT&T (T) and Coca-Cola (KO) appeared cheaper than usual. Today, I will discuss another example of a situation, where I had to dig deeper, before obtaining the full picture behind Abbott Lab’s valuation. I have been a shareholder of Abbott Labs (ABT) for many years. Just...

Not long after I wrote about this big health care firm in December 2010, this stock began a nice hot streak. It's now up 31% in the past 12 months, compared with a 14% gain for the S&P 500 during the same time. This is undoubtedly a great-performing stock. But when I first suggested investing in [...]

Here we model the evolution of Abbot Laboratories’ (NYSE: ABT) stock price since July 2003. Abbot is a company from healthcare sector of the S&P 500 index. We model a share price decomposing it into a weighted sum of two consumer price indices....

Introduction: Abbott Laboratories (NYSE:ABT)Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; dyslipidemia; HIV infection; prostate cancer, endometriosis and central precocious puberty, and anemia caused by uterine fibroids; respiratory syncytial virus; adult [...]

Abbott Laboratories (ABT) engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a dividend aristocrat which has increased distributions for 39 years in a row. The most recent dividend increase was in February 2011, when the Board of Directors approved a 9.10% increase in the quarterly dividend to 48 cents/share....

In January, I told you how you can double or even triple your yield by selling "covered" calls on your dividend stocks. While this is a safe and highly effective strategy, selling covered calls does have a drawback - of a sort. If the stock you're holding rises in price before the calls you sold expire, you could be forced to sell the shares at the option's designated strike price. This isn't likely to be a huge problem since you'll be selling your stock at a profit. The...

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company that is a leading maker of drugs, nutritional products, diabetes monitoring devices, and diagnostics. In mid-October 2011, Abbott announced plans to split the company. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these...

Abbot Labs announced earlier that it is splitting up into two companies. It will spin off its proprietary drug business by the end of 2012 and retain the rest of its businesses under the Abbott name. At $82 Billion in market value, Abbott is too large of a company to attract my interest, but whenever [...]

Give ETF issuers this much credit: In 2011,

Company Profile Abbott Laboratories (NYSE:ABT) was incorporated in 1888 and is engaged in discovery, development, manufacturing and selling of health care products around the globe. Based in Abbot Park, Illinois, the company offers adult and pediatric pharmaceuticals for rheumatoid and psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn’s disease, HIV infection, dyslipidemia, prostate cancer, endometriosis, anemia, hypothyroidism [...]

 Abbott Laboratories, long known for selling a mix of drugs, medical implants and baby formula, said Wednesday it will spin off its branded drug business and become two separate companies with more distinct identities. The split-up frees Abbott from the risks and obligations of developing innovative pharmaceutical drugs, leaving the company with a more predictable business [...]

Investors can read about many dividend capturing strategies, most of them work better on paper than they do in practice. I tried just about everything over the years, and I learned quickly it is better to use a sim account first. Now I use a few methods that produce consistent results. In this article we [...]

Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. The phase II BEAM study was conducted [...]

Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA [...]

Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type [...]

Linked here is a detailed quantitative analysis of Abbott Laboratories (ABT). Below are some highlights from the above linked analysis: Company Description: Abbott Laboratories is a diversified life science company and is a leading maker of drugs, nutritional products, diabetes monitoring devices, and diagnostics. Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a...

Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product in its portfolio for this indication – AndroGel 1%. However, Abbott Labs said that AndroGel [...]

It’s still early but our Buy List is doing very well today. Right now, we’re up 1.10% which gives us a gain of 10.64% for the year. Ford had been the big gainer today but it’s given some back. Fiserv ($FISV), Joey Banks ($JOSB) and Oracle ($ORCL)...

Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter [...]

Southwest Airlines Co. (NYSE: LUV) plunged as much as 5% in Monday's pre-market trading after the company  said that said that it will scrub 100 more flights today and reported “small, subsurface cracks” in two jets during inspections for metal fatigue after a plane’s fuselage tore open in flight. The dropped flights follow 300 cancellations yesterday, or 9 percent of the schedule, said Chris Mainz, a spokesman. Checks on 21 Boeing Co. 737-300 planes found two that needed repair, and...

Abbott Laboratories (NYSE:ABT) has announced that it is reworking to combine its American and international business.Abbott Laboratories (NYSE:ABT) Reworks Business UnitsThis idea was put forward due to the upcoming retirement of the head of Abbott Laboratories’ (NYSE:ABT) U.S. pharmaceutical business, Mr. Donald Patton.Company spokesman Scott Stoffel said on Tuesday that “Patton has been the senior [...]

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a dividend aristocrat which has increased distributions for 38 years in a row. Over the past decade this dividend stock has delivered an annualized total return of 3.10% to its loyal shareholders. The company has managed to deliver an average...

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company is a dividend aristocrat which has increased distributions for 38 years in a row. Over the past decade this dividend stock has delivered an annualized total return of 3.10% to its loyal shareholders. The company has managed to deliver an average...

Abbott Laboratories (NYSE:ABT) has received approval for TREK Coronary Balloon Systems in the US and Japan.Abbott Laboratories (NYSE:ABT) Wins Balloon ApprovalThe devices, which are available in two designs called TREK and MINI-TREK, are Coronary Dilatation Catheters for the treatment of coronary artery disease.The Trek systems which had received the CE mark in May 2010 are [...]

The pharmaceutical juggernaut Abbott Laboratories looks reasonably cheap these days. Its shares have been going down for the past few weeks and it's a good buying opportunity in my opinion. Here's why. Consistent Dividend Growth Abbott has grown dividends consistently for over 25 years. It's part of the Dividend Aristocrats index maintained by S&P. Not only that, but ABT has grown dividends an annualized 9.33% over the last 11 years. On average, the year-over-year dividend growth has also...

Abbott Laboratories (NYSE: ABT) is scheduled to release its fourth-quarter earnings before the opening bell on Wednesday, January 26, 2011. Analysts, on average, expect the company to report earnings of $1.29 per share on revenue of $9.89 billion. In the year ago quarter, the company reported earnings of $1.18 per share on revenue of $8.79 billion. Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The Company operates...

Several news stories could affect individual companies today.The following stocks should see some movement: Canon Inc. (NYSE:CAJ), Coca-Cola Co. (NYSE:KO), Abbott Laboratories (NYSE:ABT).Here is a more detailed look at stories affecting the firms' stock prices.Canon Inc. (NYSE:CAJ)[wikichart align="right" ticker="NYSE:CAJ" showannotations="false" livequote="true" startdate="26-10-2009" enddate="19-01-2011" width="300" height="245"]Canon (NYSE:CAJ) USA has been recognized by Buyers Laboratory,...

Below are a number of today's news stories relating to individual companies.The following stocks should see some movement: Abbott Laboratories (NYSE:ABT), Sunoco (NYSE:SUN), CHS (NYSE:CHS).Here is a more detailed look at stories affecting the firms' stock prices.Abbott Laboratories (NYSE:ABT)[wikichart align="right" ticker="NYSE:ABT" showannotations="false" livequote="true" startdate="26-10-2009" enddate="18-01-2011" width="300" height="245"]Abbott Laboratories (NYSE:ABT) has announced Ozespa...

Here's a run-down of Abbott Laboratories (NYSE:ABT) news stories from this week. Abbott Laboratories (NYSE:ABT) shares ended the week at 46.89 (as of 1/14/2011).Weekly News Roundup: Abbott Laboratories (NYSE:ABT)Tuesday 11 JanuaryAbbott Laboratories (NYSE:ABT) has announced it will launch the first absorbable stent in Europe.Stents are mesh- metal tubes capable of opening up human arteries after [...]

Abbott Laboratories (NYSE:ABT) has gained only less from the purchase of Piramal Healthcare's domestic formulations business.Abbott Laboratories (NYSE:ABT) shares were at 47.58 at the end of the last day's trading. There's been a -10.6% change in the stock price over the past 3 months.Abbott Laboratories (NYSE:ABT) Acquisition Still In The RedEven three months after the [...]

Several news stories could affect individual companies today.The following listed companies should see some movement: Coca-Cola Co. (NYSE:KO), Humana (NYSE:HUM), Abbott Laboratories (NYSE:ABT).Here is a more detailed look at stories affecting the firms' stock prices.Coca-Cola Co. (NYSE:KO)[wikichart align="right" ticker="NYSE:KO" showannotations="false" livequote="true" startdate="26-10-2009" enddate="11-01-2011" width="300" height="245"]Coca-Cola (NYSE:KO) and Indian School of Business have...

Abbott Laboratories (NYSE:ABT) has announced that their HIV-drug patent was rejected in India.Abbott Laboratories (NYSE:ABT) HIV Drug Patent RejectedBecause the Indian Patent Act does not permit the patenting of incremental innovations, the Indian consumer advocates succeeded in throwing out the Kaletra drug sold by Abbott Laboratories (NYSE:ABT).With this decision, the domestic generic drug makers who [...]

Here are several news stories affecting stocks today.The following companies should see some movement: Abbott Laboratories (NYSE:ABT), Siemens (NYSE:SI), Colgate-Palmolive Company (NYSE:CL).Here is a more detailed look at stories affecting the firms' stock prices.Abbott Laboratories (NYSE:ABT)[wikichart align="right" ticker="NYSE:ACN" showannotations="false" livequote="true" startdate="26-10-2009" enddate="04-01-2011" width="300" height="245"]Accenture Plc (NYSE:ACN) has appointed Pierre...